SIRT1在肿瘤耐药中的作用研究进展  

Research progress on the role of SIRT1 in tumor resistance

作　　者：夏小艳 周小明[2] 李耀军 

机构地区：[1]长沙卫生职业学院科研处,湖南410100 [2]湖南中医药大学第一附属医院中医内科,长沙410000 [3]长沙卫生职业学院临床医技系,湖南410100

出　　处：《中国临床新医学》2017年第9期930-933,共4页CHINESE JOURNAL OF NEW CLINICAL MEDICINE

基　　金：湖南省教育厅科学研究项目(编号:16C0127)

摘　　要：恶性肿瘤的多药耐药是目前治疗的瓶颈。表观遗传学与肿瘤多药耐药之间的关系引起了越来越多研究者的关注,作为表观遗传学领域的后起新星沉默信息调节因子1(SIRT1)与肿瘤多药耐药的关系成为近年来的研究热点。SIRT1是细胞生理及病理过程如细胞增值、分化、DNA损伤与应激反应、衰老及肿瘤的形成的关键调节器。该文对SIRT1对肿瘤作用及耐药性进行文献回顾,为寻找SIRT1调节剂特别是恶性肿瘤的治疗提供新思路。Muhidrug resistance of malignant tumors is the bottleneck of anti-tumor treatment at present. More and more researchers pay attention to the relationship between epigenetics and multidrug resistance. As a promising new star in the field of epigenetics study, Silent information regulator 1 （ SIRT1 ） has become a hot research topic in recent years because of its relationship with multidrug resistance of tumors. SIRT1 is a key regulator of cellular physi- ology and pathological processes such as cell proliferation, differentiation, DNA damage and stress response, aging and tumor formation. In this paper, we review the anti-tumor effect of SIRT1 and its drug resistance to provide a new idea for the treatment of malignant tumors using SIRT1 modulators.

关 键 词：沉默信息调节因子1 肿瘤多药耐药 治疗 

分 类 号：R730[医药卫生—肿瘤]